Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)

点击翻译按钮获取中文摘要

PROJECT SUMMARY/ABSTRACT Opioid Use Disorder (OUD) is a chronic, recurring condition that if left untreated, poses a significant and ongoing public health threat. OUD is associated with significant impairments in physical and psychological health including increased mortality and high utilization of emergency medical care as well as increased risk of Hepatitis C and HIV infection and Neonatal Abstinence Syndrome (NAS). OUD is also associated with increased justice and child welfare systems involvement. Currently, the number of empirically supported behavioral interventions for the treatment of OUDs is limited, the majority of which cannot be tailored (customized) to meet the unique needs of the individual client. As such, the relapse rate for individuals with OUDs remains high. Virtual reality cue exposure (VRCE) has shown considerable promise in addressing substance craving, one of the most salient components of OUD. Through repeated exposure to substance use cues within a controlled virtual environment, over time these virtual exposures weaken the relationship between substance use cues and craving, potentially leading to decreased substance use and lower probability of substance relapse. Unfortunately, currently available commercial VR products lack the essential ability to easily and repeatedly update exposure environments to introduce novelty or incorporate new or evolving substance use cues. This limitation results in less user engagement over time, potentially leading to user disengagement and premature treatment termination. Through the R41 project titled “Modular Adaptive Virtual Reality Intervention for Clinical Substance use disorder (MAVRICS)”, the research aims to improve upon currently available commercial virtual reality (VR) products designed to address substance misuse by developing a novel subscription-based software product (Helix) that supports ongoing customization of virtual reality-based cue exposure (VRCE) environments resulting in a tailored intervention addressing substance craving. Through the I-Corp program, the commercial potential for Helix will be further explored and five hypotheses pertaining to various commercial aspect of Helix will be tested through a series of interviews with potential customers and experts in the field of OUD treatment.